Research Progress on the Therapeutic Effect and Mechanism of Metformin for Lung Cancer (Review)

Overview

Journal Oncol Rep

Specialty Oncology

Date 2022 Nov 11

PMID 36367180

Authors

Pengkai Han

Junhao Zhou

Jianhua Xiang

Qiping Liu

Kai Sun

Affiliations

Soon will be listed here.

Abstract

Lung cancer is the most common type of cancer and the leading cause of cancer‑associated death worldwide. Despite the availability of various treatments such as surgery, chemoradiotherapy, targeted drugs and immunotherapy, treatment is expensive and the prognosis remains poor. At present, lung cancer drugs and treatment programs remain in a state of continuous exploration and research to improve the prognosis, and to reduce the pain and economic burden for the patients. Type 2 diabetes is a common chronic disease in middle‑aged and elderly patients, leading to significantly increased complications of cardiovascular and cerebrovascular diseases. Epidemiology shows that type 2 diabetes also increases the incidence of malignant tumors, including lung, liver, colorectal and pancreatic cancer. Metformin is a biguanide, widely used as a first‑line oral drug in treating type 2 diabetes. Metformin has a hypoglycemic effect and a biological antitumor impact, reducing the incidence of various tumors, including lung cancer, and improving the prognosis of patients with tumors. The anti‑lung cancer effect of metformin involves a variety of mechanisms that can improve the therapeutic effect and prognosis of lung cancer, as a single drug or in combination with other therapies. The present study aims to review the associated literature and the therapeutic effects of metformin on lung cancer.

Citing Articles

Risk factors for chronic postsurgical pain following thoracoscopic surgery for lung cancer.

Chen B, Shi G, Gao P Am J Transl Res. 2025; 16(12):7959-7971.

PMID: 39822545 PMC: 11733354. DOI: 10.62347/NHTK3687.

PSENEN influences the progression of renal clear cell carcinoma by regulating the immune microenvironment and oxidative phosphorylation.

Huang C, Chen K, Zhu S, Yang X, Hou J, Gu X PeerJ. 2024; 12:e18457.

PMID: 39624136 PMC: 11610461. DOI: 10.7717/peerj.18457.

Metformin reduces basal subpopulation and attenuates mammary epithelial cell stemness in FVB/N mice.

Shan M, Cheng Q, Parris A, Kong L, Yang X, Shi Y Front Cell Dev Biol. 2024; 12:1427395.

PMID: 39055652 PMC: 11269140. DOI: 10.3389/fcell.2024.1427395.

: The Two Faces of Metformin.

Goglia U, Hasballa I, Teti C, Boschetti M, Ferone D, Albertelli M Cancers (Basel). 2024; 16(7).

PMID: 38610965 PMC: 11011026. DOI: 10.3390/cancers16071287.

Will metformin use lead to a decreased risk of thyroid cancer? A systematic review and meta-analyses.

Li H, Chen Y, Hu L, Yang W, Gao Z, Liu M Eur J Med Res. 2023; 28(1):392.

PMID: 37773165 PMC: 10542235. DOI: 10.1186/s40001-023-01287-0.

References

Bitterman P, Polunovsky V . eIF4E-mediated translational control of cancer incidence. Biochim Biophys Acta. 2014; 1849(7):774-80. DOI: 10.1016/j.bbagrm.2014.09.007. View

Syngelaki A, Nicolaides K, Balani J, Hyer S, Akolekar R, Kotecha R . Metformin versus Placebo in Obese Pregnant Women without Diabetes Mellitus. N Engl J Med. 2016; 374(5):434-43. DOI: 10.1056/NEJMoa1509819. View

Okayasu S, Kitaichi K, Hori A, Suwa T, Horikawa Y, Yamamoto M . The evaluation of risk factors associated with adverse drug reactions by metformin in type 2 diabetes mellitus. Biol Pharm Bull. 2012; 35(6):933-7. DOI: 10.1248/bpb.35.933. View

Izzotti A, Balansky R, DAgostini F, Longobardi M, Cartiglia C, Micale R . Modulation by metformin of molecular and histopathological alterations in the lung of cigarette smoke-exposed mice. Cancer Med. 2014; 3(3):719-30. PMC: 4101764. DOI: 10.1002/cam4.234. View

Blandino G, Valerio M, Cioce M, Mori F, Casadei L, Pulito C . Metformin elicits anticancer effects through the sequential modulation of DICER and c-MYC. Nat Commun. 2012; 3:865. DOI: 10.1038/ncomms1859. View

Arrieta O, Barron F, Padilla M, Aviles-Salas A, Ramirez-Tirado L, Arguelles Jimenez M . Effect of Metformin Plus Tyrosine Kinase Inhibitors Compared With Tyrosine Kinase Inhibitors Alone in Patients With Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2019; 5(11):e192553. PMC: 6735425. DOI: 10.1001/jamaoncol.2019.2553. View

Berbee J, Boon M, Khedoe P, Bartelt A, Schlein C, Worthmann A . Brown fat activation reduces hypercholesterolaemia and protects from atherosclerosis development. Nat Commun. 2015; 6:6356. PMC: 4366535. DOI: 10.1038/ncomms7356. View

Zhang H, Guo X . Combinational strategies of metformin and chemotherapy in cancers. Cancer Chemother Pharmacol. 2016; 78(1):13-26. DOI: 10.1007/s00280-016-3037-3. View

Tsakiridis T, Pond G, Wright J, Ellis P, Ahmed N, Abdulkarim B . Metformin in Combination With Chemoradiotherapy in Locally Advanced Non-Small Cell Lung Cancer: The OCOG-ALMERA Randomized Clinical Trial. JAMA Oncol. 2021; 7(9):1333-1341. PMC: 8323053. DOI: 10.1001/jamaoncol.2021.2328. View

10.

Liu Y, He C, Huang X . Metformin partially reverses the carboplatin-resistance in NSCLC by inhibiting glucose metabolism. Oncotarget. 2017; 8(43):75206-75216. PMC: 5650413. DOI: 10.18632/oncotarget.20663. View

11.

Kim Y, Vagia E, Viveiros P, Kang C, Lee J, Gim G . Overcoming acquired resistance to PD-1 inhibitor with the addition of metformin in small cell lung cancer (SCLC). Cancer Immunol Immunother. 2020; 70(4):961-965. PMC: 10991863. DOI: 10.1007/s00262-020-02703-8. View

12.

Dogan Turacli I, Candar T, Yuksel B, Demirtas S . Role of metformin on base excision repair pathway in p53 wild-type H2009 and HepG2 cancer cells. Hum Exp Toxicol. 2017; 37(9):909-919. DOI: 10.1177/0960327117737145. View

13.

Liu G, Pei F, Yang F, Li L, Amin A, Liu S . Role of Autophagy and Apoptosis in Non-Small-Cell Lung Cancer. Int J Mol Sci. 2017; 18(2). PMC: 5343902. DOI: 10.3390/ijms18020367. View

14.

Skoulidis F, Goldberg M, Greenawalt D, Hellmann M, Awad M, Gainor J . Mutations and PD-1 Inhibitor Resistance in -Mutant Lung Adenocarcinoma. Cancer Discov. 2018; 8(7):822-835. PMC: 6030433. DOI: 10.1158/2159-8290.CD-18-0099. View

15.

Wang J, Xia S, Zhu Z . Synergistic effect of phenformin in non-small cell lung cancer (NSCLC) ionizing radiation treatment. Cell Biochem Biophys. 2014; 71(2):513-8. DOI: 10.1007/s12013-014-0283-z. View

16.

Prodromaki E, Korpetinou A, Giannopoulou E, Vlotinou E, Chatziathanasiadou M, Papachristou N . Expression of the microRNA regulators Drosha, Dicer and Ago2 in non-small cell lung carcinomas. Cell Oncol (Dordr). 2015; 38(4):307-17. DOI: 10.1007/s13402-015-0231-y. View

17.

Volm M, Koomagi R . Hypoxia-inducible factor (HIF-1) and its relationship to apoptosis and proliferation in lung cancer. Anticancer Res. 2000; 20(3A):1527-33. View

18.

Justus C, Sanderlin E, Yang L . Molecular Connections between Cancer Cell Metabolism and the Tumor Microenvironment. Int J Mol Sci. 2015; 16(5):11055-86. PMC: 4463690. DOI: 10.3390/ijms160511055. View

19.

Wang X, Proud C . The mTOR pathway in the control of protein synthesis. Physiology (Bethesda). 2006; 21:362-9. DOI: 10.1152/physiol.00024.2006. View

20.

Zhao D, Long X, Lu T, Wang T, Zhang W, Liu Y . Metformin decreases IL-22 secretion to suppress tumor growth in an orthotopic mouse model of hepatocellular carcinoma. Int J Cancer. 2014; 136(11):2556-65. DOI: 10.1002/ijc.29305. View